country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-163533

Copy Link Print Information

CPD-002

CPD-002 is an inhibitor for vascular endothelial growth factor receptor 2 (VEGFR 2), that inhibits angiogenesis through inhibition of VEGFR2/PI3K/AKT signaling pathway. CPD-002 exhibits anti-inflammatory activity and attenuates rheumatoid arthritis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 2617376-08-4
Formel: C₁₇H₁₆N₄O₂S
Molecular Weight:340.40

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (276 KB)

CPD-002 Chemical Structure

CAS. Nr.: 2617376-08-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle VEGFR Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
BaF3	GI₅₀	150 nM Compound: 6	Growth inhibition of mouse BaF3 cells harboring TEL-VEGFR2 incubated for 72 hrs by CCK-8 assay Growth inhibition of mouse BaF3 cells harboring TEL-VEGFR2 incubated for 72 hrs by CCK-8 assay	[PMID: 37216810]

In Vitro

CPD-002 (0-64 μM, 24-48 h) exhibits cytotoxicity for cells HUVECs and MH7A, in a dose-dependent manner^[1].
CPD-002 (0-8 μM, 24 h) inhibits VEGF-induced cell migration and invasion of HUVECs, through suppression of F-actin expression, and chemotactic response to MH7A cell-released chemoattractants^[1].
CPD-002 (0-8 μM) exhibits anti-inflammatory activity through inhibition of the inflammatory mediators like TNF-α, IL-1β, IL-6, IL-8, MMP2 and MMP9, and thus inhibits synovial angiogenesis^[1].
CPD-002 (0-8 μM, 9 days) inhibits HUVECs tube formation and aortic ring sprout formation in ex vivo rat aortic ring assay^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

HUVECs and MH7A
Concentration:

0-64 μM
Incubation Time:

24-48 h
Result:

Inhibited cell viability in a dose-dependent manner.

Cell Migration Assay ^[1]

Cell Line:

HUVECs
Concentration:

0-8 μM
Incubation Time:

24 h
Result:

Inhibited HUVECs migration in a dose-dependent manner.

In Vivo

CPD-002 (15-60 mg/kg, i.p., once daily for 14 days) exhibits anti-arthritic and anti-angiogenic effects in adjuvant-induced arthritisrats rats model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

adjuvant-induced arthritis (AIA) Sprague Dawley rats models^[1]
Dosage:

15-60 mg/kg
Administration:

i.p., once daily for 14 days
Result:

Ameliorated paw swelling, joint damage, and synovial angiogenesis.

Chemical Information

CAS. Nr. 2617376-08-4
Molecular Weight 340.40
Formel C₁₇H₁₆N₄O₂S
SMILES

CNC(C1=CC=CC=C1SC2=CC3=C(C(NC(C)=O)=NN3)C=C2)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Jiang F, et al., CPD-002, a novel VEGFR2 inhibitor, relieves rheumatoid arthritis by reducing angiogenesis through the suppression of the VEGFR2/PI3K/AKT signaling pathway. Int Immunopharmacol. 2024 Apr 20;131:111850. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

CPD-002

Alle VEGFR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

CPD-002 Related Classifications

HY-163533 Related Classifications